Sogou Inc. (SOGO) Is At $8.52 Formed Wedge; Nektar Therapeutics (NKTR) Shorts Lowered By 9.81%

April 12, 2018 - By Jerrie Dane

Nektar Therapeutics (NASDAQ:NKTR) Logo

Nektar Therapeutics (NASDAQ:NKTR) had a decrease of 9.81% in short interest. NKTR’s SI was 9.30M shares in April as released by FINRA. Its down 9.81% from 10.32 million shares previously. With 2.39 million avg volume, 4 days are for Nektar Therapeutics (NASDAQ:NKTR)’s short sellers to cover NKTR’s short positions. The SI to Nektar Therapeutics’s float is 5.95%. The stock increased 0.03% or $0.03 during the last trading session, reaching $102.77. About 1.51 million shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 347.01% since April 12, 2017 and is uptrending. It has outperformed by 335.46% the S&P500.

Sogou Inc. (SOGO) formed wedge down with $7.92 target or 7.00% below today’s $8.52 share price. Sogou Inc. (SOGO) has $3.30 billion valuation. The stock decreased 2.07% or $0.18 during the last trading session, reaching $8.52. About 1.27 million shares traded. Sogou Inc. (NYSE:SOGO) has 0.00% since April 12, 2017 and is . It has underperformed by 11.55% the S&P500.

Nektar Therapeutics develops drug candidates based on its PEGylation and polymer conjugate technology platforms in the United States. The company has market cap of $16.54 billion. The Company’s product pipeline includes drug candidates in therapeutic areas comprising cancer, auto-immune disease, and chronic pain. It currently has negative earnings. The firm offers MOVANTIK, an oral peripherally-acting opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain; MOVENTIG for the treatment of opioid-induced constipation in adult patients who have an inadequate response to laxatives; and ADYNOVATE for use in treating Hemophilia A.

Among 9 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Nektar Therapeutics had 25 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Buy” rating by Aegis Capital given on Tuesday, November 8. H.C. Wainwright reinitiated the shares of NKTR in report on Monday, April 2 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Hold” rating given on Wednesday, August 26 by TheStreet. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Thursday, November 9 by Canaccord Genuity. The firm has “Buy” rating given on Tuesday, May 30 by Roth Capital. The rating was maintained by Roth Capital with “Buy” on Monday, September 21. Jefferies maintained Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, October 18 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Mizuho on Friday, April 6. The firm has “Buy” rating by Cowen & Co given on Monday, April 9. Jefferies maintained Nektar Therapeutics (NASDAQ:NKTR) on Wednesday, November 8 with “Buy” rating.

Since December 13, 2017, it had 0 insider buys, and 11 insider sales for $40.88 million activity. 4,879 shares valued at $404,664 were sold by Nicholson John on Friday, February 16. 2,545 Nektar Therapeutics (NASDAQ:NKTR) shares with value of $211,082 were sold by Thomsen Jillian B.. Shares for $4.64M were sold by ROBIN HOWARD W on Wednesday, December 13. On Friday, February 16 the insider Hora Maninder sold $238,453. KUEBLER CHRISTOPHER A sold $1.76 million worth of stock or 30,000 shares. On Friday, February 16 the insider Labrucherie Gil M sold $288,382. 2,426 shares were sold by Doberstein Stephen K, worth $201,212 on Friday, February 16.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart